Sustained improvement in dark-adapted sensitivity but not BCVA after voretigene neparvovec treatment in a mainland Chinese child with biallelic RPE65-associated LCA2: a case report
- DOI
- 10.3389/fphar.2026.1888954
- Published
- 2026-09-03
- Container
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.3389/fphar.2026.1888954,
title = {Sustained improvement in dark-adapted sensitivity but not BCVA after voretigene neparvovec treatment in a mainland Chinese child with biallelic RPE65-associated LCA2: a case report},
author = {Yue Ren and Shu Liu and Yanbo Liu and Di Wang and Jia Rong and Wensheng Li and Chunhui Zheng and Ling Xu and Jun Li and Zhuoshi Wang and Jijing Pang},
year = {2026},
journal = {Frontiers in Pharmacology},
doi = {10.3389/fphar.2026.1888954},
url = {https://doi.org/10.3389/fphar.2026.1888954}
}RIS
TY - JOUR TI - Sustained improvement in dark-adapted sensitivity but not BCVA after voretigene neparvovec treatment in a mainland Chinese child with biallelic RPE65-associated LCA2: a case report AU - Yue Ren AU - Shu Liu AU - Yanbo Liu AU - Di Wang AU - Jia Rong AU - Wensheng Li AU - Chunhui Zheng AU - Ling Xu AU - Jun Li AU - Zhuoshi Wang AU - Jijing Pang PY - 2026 JO - Frontiers in Pharmacology DO - 10.3389/fphar.2026.1888954 UR - https://doi.org/10.3389/fphar.2026.1888954 ER -
APA
Ren, Y., Liu, S., Liu, Y., Wang, D., Rong, J., Li, W., Zheng, C., Xu, L., Li, J., Wang, Z., & Pang, J. (2026). Sustained improvement in dark-adapted sensitivity but not BCVA after voretigene neparvovec treatment in a mainland Chinese child with biallelic RPE65-associated LCA2: a case report. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2026.1888954
Source records
- crossref · retrieved 2026-09-25T10:05:21.722Z